ADMA Biologics

Evidence of pricing and mix strength comes from expanding gross margins and ASCENIV’s premium positioning. In Q1 2026, total revenue was essentially flat year over year at 114.5 million, but gross margin expanded to about 71 percent on richer mix and yields.

Management also noted persistent pressure in standard IG, which weighed on BIVIGAM volumes and likely pricing. The recent pediatric label expansion increases ASCENIV’s addressable market and should sustain premium positioning. Latent pricing power is therefore concentrated in ASCENIV rather than in the commoditizing portions of standard IG.

Key watch items: payer dynamics, site‑of‑care mix, and competitor supply ramp.